Investor Presentation March 2023

Strong Growth¹ CAGR Annual Revenue ($ millions) CAGR +109% ~0% $89.6 $60.5 $43.6 $24.6 $22.7 $20.4 $24.2 $26.3 $547.7 FY'14 FY'15 FY'16 FY'17 FY'18 FY'19 FY'20 FY'21 FY'22 New leadership YTD Revenue ($ millions) Q1'22 YTD Growth +46% $84.2 Q1'23 YTD and strategic plan 1 Fiscal 2021 results include contribution from the acquisitions of HistoTox, Bolder BioPATH and Gateway, which were completed on Apr 30, May 3 and Aug 2, respectively; Fiscal 2022 includes partial Q1 contributions from Envigo and Plato BioPharma, partial Q2 contributions from Integrated Laboratory Systems ("ILS") and Orient BioResource, partial Q3 contributions from Histion and partial Q4 contributions from Protypia. $122.8 9

View entire presentation